Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis

myVectraTM Enables Secure Access to Vectra® DA Test Results SOUTH SAN FRANCISCO, Calif., May 11, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that it has launched a new web-based portal called myVectra for patients with rheumatoid arthritis (RA).  myVectra provides patients with easy access to their Vectra […]

Read More

United States Patent and Trademark Office Grants Patent for Vectra® DA

SALT LAKE CITY, Dec. 1, 2015 (GLOBE NEWSWIRE) – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual property protection for Crescendo Bioscience’s Vectra® DA […]

Read More

Crescendo Bioscience Announces that New Studies with Vectra® DA Data Will Be Presented at the American College of Rheumatology 2015 Annual Meeting

Studies Highlight Vectra DA for Assessing Treatment Response in Rheumatoid Arthritis SALT LAKE CITY, Utah, Nov. 7, 2015 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that new data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at […]

Read More

Crescendo Bioscience Highlights New Studies with Vectra® DA that Will Be Presented at the American College of Rheumatology 2015 Annual Meeting

SALT LAKE CITY, Utah, Oct. 22, 2015 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that new data on Vectra DA will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting being held Nov. 7-11, 2015 in San Francisco, Calif. A list of the […]

Read More